KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers--

Written By Mukul Verma

Clinical Trial of DSP107 in AML, MDS and T-cell Lymphoproliferative Diseases to be Conducted at MD Anderson

Mukul Verma
Previous

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
Next

Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson